Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00255801 · FLOW

Participant flow

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma · Source last updated 2018-08-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
    id
    FG000
    title
    Doxil and Targretin® (Bexarotene)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
    id
    FG000
    title
    Doxil and Targretin® (Bexarotene)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice